14th Apr 2020 15:09
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms E Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 28 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Connor | |||
b) | Position/status | President, Global Vaccines | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 85 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Conrad | |||
b) | Position/status | SVP, Human Resources | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 1 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr N Hirons | |||
b) | Position/status | SVP, Global Ethics & Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 18 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms S Jackson | |||
b) | Position/status | SVP, Global Communications and CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 79 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Jackson | |||
b) | Position/status | PCA of Ms S Jackson (SVP, Global Communications and CEO Office) | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 28 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr L Miels | |||
b) | Position/status | President, Global Pharmaceuticals | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 4 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Redfern | |||
b) | Position/status | Chief Strategy Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 97 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Simard | |||
b) | Position/status | President, Pharmaceuticals Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 28 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr P C Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 56 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Waterhouse | |||
b) | Position/status | Chief Executive Officer of ViiV Healthcare | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 77 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms V Whyte | |||
b) | Position/status | Company Secretary | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020, on shares held through the Company's Share Reward Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.3562 | 71 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2020-04-09 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
Related Shares:
Glaxosmithkline